Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 14,687 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 14,687 shares of the business’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $41.68, for a total transaction of $612,154.16. Following the transaction, the chief executive officer owned 29,838 shares in the company, valued at $1,243,647.84. The trade was a 32.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total transaction of $552,372.84.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total transaction of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total value of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.32, for a total value of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total value of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total value of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total transaction of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total transaction of $143,510.40.

Phibro Animal Health Price Performance

Phibro Animal Health stock opened at $41.61 on Friday. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32. The company has a 50-day moving average price of $40.28 and a 200 day moving average price of $37.41. Phibro Animal Health Corporation has a 12-month low of $16.16 and a 12-month high of $46.42. The stock has a market cap of $1.69 billion, a P/E ratio of 25.07, a PEG ratio of 1.19 and a beta of 0.79.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.15. The business had revenue of $363.89 million during the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Sell-side analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were paid a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, November 26th. This represents a $0.48 annualized dividend and a yield of 1.2%. Phibro Animal Health’s dividend payout ratio (DPR) is 28.92%.

Hedge Funds Weigh In On Phibro Animal Health

Several institutional investors have recently bought and sold shares of the company. Capricorn Fund Managers Ltd purchased a new stake in Phibro Animal Health during the 3rd quarter worth about $10,233,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Phibro Animal Health during the 3rd quarter worth about $8,931,000. Voya Investment Management LLC boosted its holdings in Phibro Animal Health by 44.3% in the first quarter. Voya Investment Management LLC now owns 31,894 shares of the company’s stock valued at $681,000 after purchasing an additional 9,796 shares in the last quarter. Bailard Inc. acquired a new position in Phibro Animal Health in the second quarter valued at approximately $259,000. Finally, Squarepoint Ops LLC purchased a new position in Phibro Animal Health in the second quarter valued at approximately $813,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PAHC. JPMorgan Chase & Co. increased their price target on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Phibro Animal Health has an average rating of “Hold” and a consensus target price of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.